Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Clinical and Translational Science
|
April 21, 2022
Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies
Morris Muliaditan, Armin Sepp
Mabs
|
May 3, 2024
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies
Armin Sepp, Morris Muliaditan
British Journal of Pharmacology
|
October 2, 2021
Bacterial growth dynamics and pharmacokinetic-pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice
Morris Muliaditan, Oscar Della Pasqua
British Journal of Clinical Pharmacology
|
May 17, 2020
Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis
Morris Muliaditan, Oscar Della Pasqua
The Journal of Antimicrobial Chemotherapy
|
July 31, 2019
How long will treatment guidelines for TB continue to overlook variability in drug exposure?
Morris Muliaditan, Oscar Della Pasqua
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 6, 2022
Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection
Morris Muliaditan, Donato Teutonico, Fatima Ortega-Muro, et al.
Drug Discovery Today
|
October 4, 2016
The implications of model-informed drug discovery and development for tuberculosis
Morris Muliaditan, Geraint R Davies, Ulrika S H Simonsson, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 11, 2020
Optimizing β-Lactams against Tuberculosis
Veronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development
Sebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 22, 2025
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making
Herbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Clinical and Translational Science
|
April 21, 2022
Application of quantitative protein mass spectrometric data in the early predictive analysis of target engagement by monoclonal antibodies
Morris Muliaditan, Armin Sepp
Mabs
|
May 3, 2024
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies
Armin Sepp, Morris Muliaditan
British Journal of Pharmacology
|
October 2, 2021
Bacterial growth dynamics and pharmacokinetic-pharmacodynamic relationships of rifampicin and bedaquiline in BALB/c mice
Morris Muliaditan, Oscar Della Pasqua
British Journal of Clinical Pharmacology
|
May 17, 2020
Evaluation of pharmacokinetic-pharmacodynamic relationships and selection of drug combinations for tuberculosis
Morris Muliaditan, Oscar Della Pasqua
The Journal of Antimicrobial Chemotherapy
|
July 31, 2019
How long will treatment guidelines for TB continue to overlook variability in drug exposure?
Morris Muliaditan, Oscar Della Pasqua
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences
|
March 6, 2022
Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection
Morris Muliaditan, Donato Teutonico, Fatima Ortega-Muro, et al.
Drug Discovery Today
|
October 4, 2016
The implications of model-informed drug discovery and development for tuberculosis
Morris Muliaditan, Geraint R Davies, Ulrika S H Simonsson, et al.
American Journal of Respiratory and Critical Care Medicine
|
January 11, 2020
Optimizing β-Lactams against Tuberculosis
Veronique R de Jager, Naadira Vanker, Lize van der Merwe, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 22, 2025
Tutorial on Conditional Simulations With a Tumor Size-Overall Survival Model to Support Oncology Drug Development
Sebastiaan C Goulooze, Morris Muliaditan, Richard C Franzese, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
February 22, 2025
Development of a Joint Tumor Size-Overall Survival Modeling and Simulation Framework Supporting Oncology Development Decision-Making
Herbert Struemper, Chetan Rathi, Morris Muliaditan, et al.
Page
of 2